Andere Sprachen C4 Therapeutics, Inc.

Aktien

A2QC0X

US12529R1077

CCCC

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
6.17 ^USD	-1.12%		-8.18%	+9.20%

08.04.	C4 Therapeutics, Inc. stellt auf der Jahrestagung 2024 der American Association for Cancer Research neue präklinische Daten für CFT1946 vor, die eine überlegene Aktivität als Einzelwirkstoff im Vergleich zu klinisch zugelassenen Standardkombinationen von BRAF-Inhibitoren zeigen	CI
04.03.	C4 Therapeutics arbeitet mit der deutschen Merck KGaA zusammen, um die Forschung an zielgerichteten Krebstherapien voranzutreiben	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum	09.04.
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	08.04.
C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	08.04.
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to S&P Biotechnology Select Industry Index	18.03.
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024	06.03.
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024	05.03.
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024	05.03.
C4 Therapeutics Collaborating With Germany's Merck KGaA to Advance Research on Targeted Therapies for Cancer	04.03.
C4 Therapeutics : Corporate Presentation – March 2024	04.03.
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins	04.03.
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins	04.03.
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA Against Critical Oncogenic Proteins	04.03.
C4 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.02.
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	22.02.
North American Morning Briefing : Stock Futures -2-	21.02.
North American Morning Briefing : Microsoft Kicks -2-	30.01.
C4 Therapeutics Shares Jump After JPMorgan Upgrade	29.01.
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines	09.01.
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines	09.01.
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals	04.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen C4 Therapeutics, Inc.

Aktien

A2QC0X

US12529R1077

CCCC

Andere Sprachen

Filter